Advertisement

Application of Machine Learning Approaches to Identify New Anticonvulsant Compounds Active in the 6 Hz Seizure Model

  • S. Goicoechea
  • M. L. Sbaraglini
  • S. R. Chuguransky
  • J. F. Morales
  • M. E. Ruiz
  • A. Talevi
  • C. L. BelleraEmail author
Conference paper
First Online:
Part of the Communications in Computer and Information Science book series (CCIS, volume 1068)

Abstract

Epilepsy is the second most common chronic brain disorder, affecting 65 million people worldwide. According to the NIH’s Epilepsy Therapy Screening Program, evaluation of potential new antiepileptic drug candidates begins with assessment of their protective effects in two acute seizure models in mice, the Maximal Electroshock Seizure test and the 6 Hz test. The latter elicits partial seizures through an electrical stimulus of 44 mA, at which many clinically established anti-seizure drugs do not suppress seizures. The inclusion of this “high-hurdle” acute seizure assay at the initial stage of the drug identification phase is intended to increase the probability that agents with improved efficacy will be detected. In this work, we have used machine learning approximations to develop in silico models capable of identifying novel anticonvulsant drugs with protective effects in the 6 Hz seizure model. Linear classifiers based on Dragon conformation-independent descriptors were generated through an in-house routine in R environment and validated through standard validation procedures. They were later combined through different ensemble learning schemes. The best ensemble comprised the 29 best-performing models combined using the MIN operator. With the objective of finding new drug repurposing opportunities (i.e. identifying second or further therapeutic indications, in our case anticonvulsant activity, in existing drugs), such model ensemble was applied in a virtual screening campaign of DrugBank and Sweetlead databases. 28 approved drugs were identified as potential protective agents in the 6 Hz model. The present study constitutes an example of the use of machine learning approximations to systematically guide drug repurposing projects.

Keywords

Machine learning Ensemble learning 6 Hz seizure model Anticonvulsant drugs Virtual screening Epilepsy Drug repurposing 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors would like to thank the following public and non-profit organisations: National University of La Plata (UNLP) and Argentinean National Council of Science and Technological Research (CONICET).

Funding

Support was received from the National University of La Plata (UNLP) [grant X729].

Supplementary material

492884_1_En_1_MOESM1_ESM.zip (556 kb)
Supplementary material 1 (ZIP 556 kb)

References

  1. 1.
    World Health Organization: Fact Sheet Epilepsy. https://www.who.int/news-room/fact-sheets/detail/epilepsy
  2. 2.
    Xia, L., Ou, S., Pan, S.: Initial response to antiepileptic drugs in patients with newly diagnosed epilepsy as a predictor of long-term outcome. Front. Neurol. 8, 658 (2017).  https://doi.org/10.3389/fneur.2017.00658CrossRefGoogle Scholar
  3. 3.
    Corsello, S.M., et al.: The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405–408 (2017).  https://doi.org/10.1038/nm.4306CrossRefGoogle Scholar
  4. 4.
    Talevi, A.: Drug repositioning: current approaches and their implications in the precision medicine era. Expert. Rev. Precis. Med. Drug Dev. 3, 49–61 (2018).  https://doi.org/10.1080/23808993.2018.1424535CrossRefGoogle Scholar
  5. 5.
    Barton, M.E., Klein, B.D., Wolf, H.H., White, H.S.: Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47, 217–227 (2001).  https://doi.org/10.1016/S0920-1211(01)00302-3CrossRefGoogle Scholar
  6. 6.
    Löscher, W.: Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 20(5), 359–368 (2011).  https://doi.org/10.1016/j.seizure.2011.01.003CrossRefGoogle Scholar
  7. 7.
    Vyskovsky, R., Schwarz, D., Janousova, E., Kasparek, T.: Random subspace ensemble artificial neural networks for first-episode Schizophrenia classification. In: Proceedings of the 2016 Federated Conference on Computer Science and Information Systems (Gdansk: FedCSIS), pp. 317–321 (2016).  https://doi.org/10.15439/2016f333
  8. 8.
    Kamiński, K., Wiklik, B., Obniska, J.: Synthesis and anticonvulsant activity of new N-phenyl-2-(4-phenylpiperazin-1-yl) acetamide derivatives. Med. Chem. Res. 24(7), 3047–3061 (2015).  https://doi.org/10.1007/s00044-015-1360-6CrossRefGoogle Scholar
  9. 9.
    Dawidowski, M., Lewandowski, W., Turło, J.: Synthesis of new perhydropyrrolo [1, 2-a] pyrazine derivatives and their evaluation in animal models of epilepsy. Molecules 19(10), 15955–15981 (2014).  https://doi.org/10.3390/molecules191015955CrossRefGoogle Scholar
  10. 10.
    Coleman, N., et al.: The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics 12(1), 234–249 (2015).  https://doi.org/10.1007/s13311-014-0305-yCrossRefGoogle Scholar
  11. 11.
    Obniska, J., Chlebek, I., Kamiński, K., Bojarski, A.J., Satała, G.: Synthesis, anticonvulsant activity and 5-HT1A/5-HT7 receptors affinity of 1-[(4-arylpiperazin-1-yl)-propyl]-succinimides. Pharmacol. Rep. 64(2), 326–335 (2012)CrossRefGoogle Scholar
  12. 12.
    Xian-Qing, D., Ming-Xia, S., Guo-Hua, G., Shi-Ben, W., Zhe-Shan, Q.: Synthesis and anticonvulsant evaluation of some new 6-(substituted-phenyl) thiazolo [3, 2-b][1, 2, 4]triazole derivatives in mice. Iran. J. Pharm. Res. 13(2), 459–469 (2014)Google Scholar
  13. 13.
    Byrtus, H., Obniska, J., Czopek, A., Kamiński, K., Pawłowski, M.: Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2, 4-diones. Bioorg. Med. Chem. 19(20), 6149–6156 (2011).  https://doi.org/10.1016/j.bmc.2011.08.017CrossRefGoogle Scholar
  14. 14.
    Florek-Luszczki, M., Wlaz, A., Luszczki, J.J.: Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6 Hz psychomotor seizure model – A type II isobolographic analysis. Eur. J. Pharmacol. 723, 410–418 (2014).  https://doi.org/10.1016/j.ejphar.2013.10.063CrossRefGoogle Scholar
  15. 15.
    Dawidowski, M., Turło, M.: Multicomponent synthesis and anticonvulsant activity of monocyclic 2, 6-diketopiperazine derivatives. Med. Chem. Res. 23(4), 2007–2018 (2014).  https://doi.org/10.1007/s00044-013-0800-4CrossRefGoogle Scholar
  16. 16.
    Ugale, V.G., Bari, S.B.: Structural exploration of quinazolin-4 (3H)-ones as anticonvulsants: rational design, synthesis, pharmacological evaluation, and molecular docking studies. Arch. Pharm. 349(11), 864–880 (2016).  https://doi.org/10.1002/ardp.201600218CrossRefGoogle Scholar
  17. 17.
    Tomaciello, F., Leclercq, K., Kaminski, R.M.: Resveratrol lacks protective activity against acute seizures in mouse models. Neurosci. Lett. 632, 199–203 (2016).  https://doi.org/10.1016/j.neulet.2016.09.002CrossRefGoogle Scholar
  18. 18.
    Sałat, K., et al.: Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. Neuropharmacol. 113(Pt A), 331–342 (2017).  https://doi.org/10.1016/j.neuropharm.2016.10.019CrossRefGoogle Scholar
  19. 19.
    Gunia-Krzyżak, A., et al.: Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH3 or 2-CH3. Bioorg. Med. Chem. 25(2), 471–482 (2017).  https://doi.org/10.1016/j.bmc.2016.11.014CrossRefGoogle Scholar
  20. 20.
    Zolkowska, D., Dhir, A., Krishnan, K., Covey, D.F., Rogawski, M.A.: Anticonvulsant potencies of the enantiomers of the neurosteroids androsterone and etiocholanolone exceed those of the natural forms. Psychopharmacol. (Berl). 231(17), 3325–3332 (2014).  https://doi.org/10.1007/s00213-014-3546-xCrossRefGoogle Scholar
  21. 21.
    Shekh-Ahmad, T., et al.: Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 55(12), 1944–1952 (2014).  https://doi.org/10.1111/epi.12857CrossRefGoogle Scholar
  22. 22.
    Kamiński, K., Wiklik, B., Obniska, J.: Synthesis, anticonvulsant properties, and SAR analysis of differently substituted pyrrolidine-2, 5-diones and piperidine-2, 6-diones. Arch. Pharm. (Weinheim) 347(11), 840–852 (2014).  https://doi.org/10.1002/ardp.201400179CrossRefGoogle Scholar
  23. 23.
    Orellana-Paucar, A.M., et al.: Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS ONE 8(12), e81634 (2013).  https://doi.org/10.1371/journal.pone.0081634CrossRefGoogle Scholar
  24. 24.
    Nieoczym, D., Socała, K., Jedziniak, P., Olejnik, M., Wlaź, P.: Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model. Prog. Neuropsychopharmacol. Biol. Psychiatry 47, 104–110 (2012).  https://doi.org/10.1016/j.pnpbp.2013.08.009CrossRefGoogle Scholar
  25. 25.
    Dawidowski, M., Wilczek, M., Kubica, K., Skolmowski, M., Turło, J.: Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo [1, 2-a]pyrazine derivatives. Bioorg. Med. Chem. Lett. 23(22), 6106–6110 (2013).  https://doi.org/10.1016/j.bmcl.2013.09.022CrossRefGoogle Scholar
  26. 26.
    Shaikh, M.F., Tan, K.N., Borges, K.: Anticonvulsant screening of luteolin in four mouse seizure models. Neurosci. Lett. 550, 195–199 (2013).  https://doi.org/10.1016/j.neulet.2013.06.065CrossRefGoogle Scholar
  27. 27.
    Buenafe, O.E., et al.: Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models. ACS. Chem. Neurosci. 4(11), 1479–1487 (2013).  https://doi.org/10.1021/cn400140eCrossRefGoogle Scholar
  28. 28.
    Kumar, D., Kumar Sharma, V., Kumar, R., Singh, T., Singh, H., Singh, A.D., Roy, R.K.: Design, synthesis and anticonvulsant activity of some new 5, 7-dibromoisatin semicarbazone derivatives. EXCLI J. 12, 628–640 (2013)Google Scholar
  29. 29.
    Wlaz, A., Kondrat-Wrobel, M.W., Zaluska, K., Kochman, E., Rekas, A.R., Luszczki, J.J.: Synergistic interaction of levetiracetam with gabapentin in the mouse 6 Hz psychomotor seizure model – A type II isobolographic analysis. Curr. Issues Pharm. Med. Sci. 28(3), 204–207 (2015).  https://doi.org/10.1515/cipms-2015-0073CrossRefGoogle Scholar
  30. 30.
    Shandra, A., Shandra, P., Kaschenko, O., Matagne, A., Stöhr, T.: Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Epilepsia 54(7), 1167–1175 (2013).  https://doi.org/10.1111/epi.12237CrossRefGoogle Scholar
  31. 31.
    Ahsan, M.J., Khalilullah, H., Yasmin, S., Singh Jadav, S., Stables, J.P.: Synthesis and anticonvulsant evaluation of 2-(substituted benzylidene/ethylidene)-N-(substituted phenyl) hydrazinecarboxamide analogues. Med. Chem. Res. 22(6), 2746–2754 (2013).  https://doi.org/10.1007/s00044-012-0271-zCrossRefGoogle Scholar
  32. 32.
    Tripathi, L., Kumar, P.: Augmentation of GABAergic neurotransmission by novel N-(substituted)-2-[4-(substituted) benzylidene] hydrazinecarbothioamides—a potential anticonvulsant approach. Eur. J. Med. Chem. 64, 477–487 (2013).  https://doi.org/10.1016/j.ejmech.2013.04.019CrossRefGoogle Scholar
  33. 33.
    Ulloora, S., Shabaraya, R., Ranganathan, R., Adhikari, A.V.: Synthesis, anticonvulsant and anti-inflammatory studies of new 1, 4-dihydropyridin-4-yl-phenoxyacetohydrazones. Eur. J. Med. Chem. 70, 341–349 (2013).  https://doi.org/10.1016/j.ejmech.2013.10.010CrossRefGoogle Scholar
  34. 34.
    Zuliani, V., Rivara, M.: In vivo screening of diarylimidazoles as anticonvulsant agents. Med. Chem. Res. 21(11), 3428–3434 (2011).  https://doi.org/10.1007/s00044-011-9869-9CrossRefGoogle Scholar
  35. 35.
    Kumar, P., Shrivastava, B., Pandeya, S.M., Tripathi, L., Stables, J.P.: Design, synthesis, and anticonvulsant evaluation of some novel 1, 3 benzothiazol-2-yl hydrazones/acetohydrazones. Med. Chem. Res. 21(9), 2428–2442 (2012).  https://doi.org/10.1007/s00044-011-9768-0CrossRefGoogle Scholar
  36. 36.
    Hebeisen, S., et al.: Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology 89, 122–1235 (2015).  https://doi.org/10.1016/j.neuropharm.2014.09.008CrossRefGoogle Scholar
  37. 37.
    Ahsan, M.J., Khalilullah, H., Stables, J.P., Govindasamy, J.: Synthesis and anticonvulsant activity of 3a, 4-dihydro-3H-indeno [1, 2-c] pyrazole-2-carboxamide/carbothioamide analogues. J. Enzyme Inhib. Med. Chem. 28(3), 644–650 (2013).  https://doi.org/10.3109/14756366.2012.663364CrossRefGoogle Scholar
  38. 38.
    Tosh, D.K., et al.: Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. J. Med. Chem. 55(18), 8075–8090 (2012)CrossRefGoogle Scholar
  39. 39.
    Mishra, R.K., Baker, M.T.: Ortho Substituent effects on the anticonvulsant properties of 4-hydroxy-trifluoroethyl phenols. Bioorg. Med. Chem. Lett. 22(17), 5608–5611 (2012).  https://doi.org/10.1016/j.bmcl.2012.07.001CrossRefGoogle Scholar
  40. 40.
    Wang, D.D., Englot, D.J., Garcia, P.A., Lawton, M.T., Young, W.L.: Minocycline and tetracycline-class antibiotics are protective against partial seizures in vivo. Epilepsy Behav. 24(3), 314–318 (2012).  https://doi.org/10.1016/j.yebeh.2012.03.035CrossRefGoogle Scholar
  41. 41.
    Dawidowski, M., Herold, F., Chodkowski, A., Kleps, J.: Synthesis and anticonvulsant activity of novel 2, 6-diketopiperazine derivatives. Part 2: Perhydropyrido [1, 2-a] pyrazines. Eur. J. Med. Chem. 48, 347–353 (2012).  https://doi.org/10.1016/j.ejmech.2011.11.032CrossRefGoogle Scholar
  42. 42.
    Gasior, M., Socała, K., Nieoczym, D., Wlaź, P.: Clavulanic acid does not affect convulsions in acute seizure tests in mice. J. Neural. Transm. 119(1), 1–6 (2012).  https://doi.org/10.1007/s00702-011-0662-1CrossRefGoogle Scholar
  43. 43.
    Perez-Llamas, C., Lopez-Bigas, N.: Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS ONE 6, e19541 (2011).  https://doi.org/10.1371/journal.pone.0019541CrossRefGoogle Scholar
  44. 44.
    Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y.D., Lee, K.H., Tropsha, A.: Rational selection of training and test sets for the development of validated QSAR models. J. Comput. Aided Mol. Des. 17, 241–253 (2003).  https://doi.org/10.1023/A:1025386326946CrossRefGoogle Scholar
  45. 45.
    Martin, T.M., et al.: Does rational selection of training and test sets improve the outcome of QSAR modeling? J. Chem. Inf. Model. 52, 2570–2578 (2012).  https://doi.org/10.1021/ci300338wCrossRefGoogle Scholar
  46. 46.
    Everitt, B.S., Landau, S., Leese, M., Stahl, D.: Cluster Analysis, 5th edn. Wiley, West Sussex (2011)CrossRefGoogle Scholar
  47. 47.
    El Habib Daho, M., Chikh, M.A.: Combining bootstrapping samples, random subspaces and random forests to build classifiers. J. Med. Imaging Health Inf. 5, 539–544 (2015).  https://doi.org/10.1166/jmihi.2015.1423CrossRefGoogle Scholar
  48. 48.
    Yu, G., Zhang, G., Domeniconi, C., Yu, Z., You, J.: Semi-supervised classification based on random subspace dimensionality reduction. Pattern Recogn. 45, 1119–1135 (2012).  https://doi.org/10.1016/j.patcog.2011.08.024CrossRefzbMATHGoogle Scholar
  49. 49.
    Toropova, A.P., Toropov, A.A.: CORAL: binary classifications (active/inactive) for drug-induced liver injury. Toxicol. Lett. 268, 51–57 (2017).  https://doi.org/10.1016/j.toxlet.2017.01.011CrossRefGoogle Scholar
  50. 50.
    Gramatica, P.: On the development and validation of QSAR models. Methods Mol. Biol. 930, 499–526 (2013).  https://doi.org/10.1007/978-1-62703-059-5_21CrossRefGoogle Scholar
  51. 51.
    Roy, K., Mitra, I.: On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design. Comb. Chem. High Throughput Screen. 14(6), 450–474 (2011).  https://doi.org/10.2174/138620711795767893CrossRefGoogle Scholar
  52. 52.
    Dietterich, T.G.: Ensemble methods in machine learning. In: Kittler, J., Roli, F. (eds.) MCS 2000. LNCS, vol. 1857, pp. 1–15. Springer, Heidelberg (2000).  https://doi.org/10.1007/3-540-45014-9_1 CrossRefGoogle Scholar
  53. 53.
    Robin, X., et al.: pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinf. 12, 77 (2011).  https://doi.org/10.1186/1471-2105-12-77CrossRefGoogle Scholar
  54. 54.
    Truchon, J.F., Bayly, C.L.: Evaluating virtual screening methods: good and bad metrics for the “early recognition” problem. J. Chem. Inf. Model. 47, 488–508 (2007).  https://doi.org/10.1021/ci600426eCrossRefGoogle Scholar
  55. 55.
    Yabuuchi, H., et al.: Analysis of multiple compound–protein interactions reveals novel bioactive molecules. Mol. Syst. Biol. 7, 472, 1–12 (2011).  https://doi.org/10.1038/msb.2011.5CrossRefGoogle Scholar
  56. 56.
    Lätti, S., Niinivehmas, S., Pentikäinen, O.T.: Rocker: open source, easy-to-use tool for AUC and enrichment calculations and ROC visualization. J. Cheminformatics 8(1), 45 (2016).  https://doi.org/10.1186/s13321-016-0158-yCrossRefGoogle Scholar
  57. 57.
    Mysinger, M.M., Carchia, M., Irwin, J.J., Shoichet, B.K.: Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55(14), 6582–6594 (2012).  https://doi.org/10.1021/jm300687eCrossRefGoogle Scholar
  58. 58.
    Alberca, L.N., et al.: Cascade ligand-and structure-based virtual screening to identify new trypanocidal compounds inhibiting putrescine uptake. Front. Cell. Infect. Microbiol. 8, 173 (2018).  https://doi.org/10.3389/fcimb.2018.00173CrossRefGoogle Scholar
  59. 59.
    Law, V., et al.: DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091–D1097 (2014).  https://doi.org/10.1093/nar/gkt1068CrossRefGoogle Scholar
  60. 60.
    Novick, P.A., Ortiz, O.F., Poelman, J., Abdulhay, A.Y., Pande, V.S.: SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. PLoS ONE 8(11), e79568 (2013).  https://doi.org/10.1371/journal.pone.0079568CrossRefGoogle Scholar
  61. 61.
    Talevi, A., Carrillo, C., Comini, M.: The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies. Curr. Med. Chem. 26 (2019).  https://doi.org/10.2174/0929867325666180926151059
  62. 62.
    Oprea, T.I., Overington, J.P.: Computational and practical aspects of drug repositioning. Assay Drug Dev. Technol. 13, 299–306 (2015).  https://doi.org/10.1089/adt.2015.29011.tiodrrrCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Laboratory of Bioactive Research and Development (LIDeB), Department of Biological Sciences, Faculty of Exact SciencesUniversity of La Plata (UNLP)La Plata, Buenos AiresArgentina
  2. 2.CCT La Plata, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)Buenos AiresArgentina

Personalised recommendations

Cite paper

Buy options